Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought

Motley Fool2021-09-09

I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

348

Report

Comment（26）

bernardtayet
·2021-09-10
Trading with care. Caution
Reply
1
Report
Jenjorjack
·2021-09-10
Buying her ETFs probably fit a 5% satellite. Too heart attack
Reply
1
Report
hohok
·2021-09-10
Like pls
Reply
1
Report
TK360
·2021-09-10
Nice
Reply
1
Report
KYHBKO
·2021-09-10
the title seems to imply a negative move but if we can buy at a good bargain, it will be good. only time will tell
Reply
1
Report
JTEnver
·2021-09-10
I guess now the question is how low it will go.
Reply
2
Report
VL505
·2021-09-10
Buy from the dip
Reply
1
Report
seojun
·2021-09-10
Ohhh here we go again
Reply
1
Report
泰格儿沫
·2021-09-10
mark
Reply
3
Report
Et1502
·2021-09-10
Aggressively Buying up everything. ?
Reply
4
Report
replaygoh
·2021-09-10
noted
Reply
3
Report
CalvinCougar
·2021-09-10
OK
Reply
5
Report
HENRYCSC
·2021-09-09
Ok
Reply
3
Report
Envyapple
·2021-09-09
Good
Reply
2
Report
Deonc
·2021-09-09
Comment and like, please
Reply
5
Report
Fold Replies
- seojun:
  alright
  2021-09-10
  Reply
  Report
- Chanelyap:
  Ok
  2021-09-09
  Reply
  Report
Rockyspider
·2021-09-09
Hello
Reply
5
Report
lesandyc
·2021-09-09
Like real
Reply
3
Report
Kundos
·2021-09-09
Thanks
Reply
4
Report
Wallstrtbets
·2021-09-09
Thanks, Cathy.
Reply
4
Report
zero79
·2021-09-09
Hope so
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2166348079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-09 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2166348079","market":"us","top_or_hot":-1,"title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","media":"Motley Fool","content":"<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRSP","symbol_name":"CRISPR Therapeutics AG","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","article_id":"2166348079","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","pubTimestamp":1631194020,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation","PSNL":"Personalis"},"translate_title":"凯西·伍德去垃圾箱跳水：她刚刚买了3只股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARKIU":0.9,"CRSP":0.9,"JE":0.9,"NVTA":0.9,"PSNL":0.9},"content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":883640226,"gmtCreate":1631239608765,"gmtModify":1676530505575,"author":{"id":"3583377018896117","authorId":"3583377018896117","name":"bernardtayet","avatar":"https://static.tigerbbs.com/43e8c1fc37a4bff2a94af98953cff267","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3583377018896117","authorIdStr":"3583377018896117"},"htmlText":"Trading with care. Caution&nbsp;","listText":"Trading with care. Caution&nbsp;","text":"Trading with care. Caution","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883640226","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883608731,"gmtCreate":1631235921423,"gmtModify":1676530503607,"author":{"id":"3554873215379647","authorId":"3554873215379647","name":"Jenjorjack","avatar":"https://static.tigerbbs.com/d9d4687aa5519f0d2fb1b18f916be861","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"idStr":"3554873215379647","authorIdStr":"3554873215379647"},"htmlText":"Buying her ETFs probably fit a 5% satellite. Too heart attack&nbsp;","listText":"Buying her ETFs probably fit a 5% satellite. Too heart attack&nbsp;","text":"Buying her ETFs probably fit a 5% satellite. Too heart attack","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883608731","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883872002,"gmtCreate":1631235363906,"gmtModify":1676530503244,"author":{"id":"3581844295426037","authorId":"3581844295426037","name":"hohok","avatar":"https://static.tigerbbs.com/b9ae72338572431c58f911b40ae0f930","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581844295426037","authorIdStr":"3581844295426037"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883872002","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883861716,"gmtCreate":1631233196335,"gmtModify":1676530502133,"author":{"id":"3574766349354741","authorId":"3574766349354741","name":"TK360","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3574766349354741","authorIdStr":"3574766349354741"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883861716","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883817420,"gmtCreate":1631232544060,"gmtModify":1676530501812,"author":{"id":"3574381076586256","authorId":"3574381076586256","name":"KYHBKO","avatar":"https://static.tigerbbs.com/c3bcbc7f9a10836dea92afc94bf39b5b","vip":2,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574381076586256","authorIdStr":"3574381076586256"},"htmlText":"the title seems to imply a negative move but if we can buy at a good bargain, it will be good. only time will tell","listText":"the title seems to imply a negative move but if we can buy at a good bargain, it will be good. only time will tell","text":"the title seems to imply a negative move but if we can buy at a good bargain, it will be good. only time will tell","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883817420","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883814351,"gmtCreate":1631232448273,"gmtModify":1676530501771,"author":{"id":"3569978357499516","authorId":"3569978357499516","name":"JTEnver","avatar":"https://static.tigerbbs.com/af69d4e71395602d8cede2c1956e94c0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569978357499516","authorIdStr":"3569978357499516"},"htmlText":"I guess now the question is how low it will go.","listText":"I guess now the question is how low it will go.","text":"I guess now the question is how low it will go.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883814351","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883174252,"gmtCreate":1631230670076,"gmtModify":1676530500764,"author":{"id":"3569876910526514","authorId":"3569876910526514","name":"VL505","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":4,"crmLevelSwitch":0,"idStr":"3569876910526514","authorIdStr":"3569876910526514"},"htmlText":"Buy from the dip&nbsp;","listText":"Buy from the dip&nbsp;","text":"Buy from the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883174252","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883129042,"gmtCreate":1631228315386,"gmtModify":1676530499628,"author":{"id":"4087771643270940","authorId":"4087771643270940","name":"seojun","avatar":"https://static.tigerbbs.com/3bd9ce06b0a58d0a81582641f6566970","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4087771643270940","authorIdStr":"4087771643270940"},"htmlText":"Ohhh here we go again","listText":"Ohhh here we go again","text":"Ohhh here we go again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883129042","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883165346,"gmtCreate":1631227967285,"gmtModify":1676530499533,"author":{"id":"3582240015316418","authorId":"3582240015316418","name":"泰格儿沫","avatar":"https://static.tigerbbs.com/4f001b92b909958f86be6097b143a711","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582240015316418","authorIdStr":"3582240015316418"},"htmlText":"mark","listText":"mark","text":"mark","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883165346","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883162132,"gmtCreate":1631227914226,"gmtModify":1676530499517,"author":{"id":"3566089803841994","authorId":"3566089803841994","name":"Et1502","avatar":"https://static.tigerbbs.com/593ec0056928c16af9027b7137674d79","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3566089803841994","authorIdStr":"3566089803841994"},"htmlText":"Aggressively Buying up everything. ?","listText":"Aggressively Buying up everything. ?","text":"Aggressively Buying up everything. ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883162132","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883189882,"gmtCreate":1631226484646,"gmtModify":1676530499148,"author":{"id":"3582963095283492","authorId":"3582963095283492","name":"replaygoh","avatar":"https://static.tigerbbs.com/d47b21291424a3d55039334a8de5cdb9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582963095283492","authorIdStr":"3582963095283492"},"htmlText":"noted","listText":"noted","text":"noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883189882","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883198541,"gmtCreate":1631222181383,"gmtModify":1676530498412,"author":{"id":"4088168670997490","authorId":"4088168670997490","name":"CalvinCougar","avatar":"https://static.tigerbbs.com/400aaa31d84fe856132900270462f631","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":6,"crmLevelSwitch":0,"idStr":"4088168670997490","authorIdStr":"4088168670997490"},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883198541","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883314948,"gmtCreate":1631201641884,"gmtModify":1676530496241,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883314948","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883976351,"gmtCreate":1631198890073,"gmtModify":1676530495158,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":1,"idStr":"3580175323096207","authorIdStr":"3580175323096207"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883976351","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883971705,"gmtCreate":1631198810707,"gmtModify":1676530495130,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3569316529855154","authorIdStr":"3569316529855154"},"htmlText":"Comment and like, please","listText":"Comment and like, please","text":"Comment and like, please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883971705","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5810726,"gmtCreate":1631228328375,"gmtModify":1663233636147,"authorId":4087771643270940,"author":{"id":4087771643270940,"idStr":"4087771643270940","authorId":4087771643270940,"name":"seojun","avatar":"https://static.tigerbbs.com/3bd9ce06b0a58d0a81582641f6566970","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883971705,"type":1,"supId":5808918,"prevId":0,"content":"alright","text":"alright","html":"alright"},{"id":5808918,"gmtCreate":1631201031724,"gmtModify":1663233627752,"authorId":3581317711527033,"author":{"id":3581317711527033,"idStr":"3581317711527033","authorId":3581317711527033,"name":"Chanelyap","avatar":"https://static.tigerbbs.com/ead5a4e57e2f9f018e7802a33c0a28f5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883971705,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":883927105,"gmtCreate":1631197657607,"gmtModify":1676530494489,"author":{"id":"3561779703230954","authorId":"3561779703230954","name":"Rockyspider","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":6,"crmLevelSwitch":0,"idStr":"3561779703230954","authorIdStr":"3561779703230954"},"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883927105","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883926642,"gmtCreate":1631197467986,"gmtModify":1676530494393,"author":{"id":"3560850463279443","authorId":"3560850463279443","name":"lesandyc","avatar":"https://static.tigerbbs.com/d76431adfa69aad1ff5ab1e357d9d9e3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3560850463279443","authorIdStr":"3560850463279443"},"htmlText":"Like real&nbsp;","listText":"Like real&nbsp;","text":"Like real","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883926642","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883962943,"gmtCreate":1631196951682,"gmtModify":1676530494186,"author":{"id":"4093470092873140","authorId":"4093470092873140","name":"Kundos","avatar":"https://community-static.tradeup.com/news/ce1a3c71cbcd8d00d16dfeac879fe818","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4093470092873140","authorIdStr":"4093470092873140"},"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883962943","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883969285,"gmtCreate":1631196717347,"gmtModify":1676530494076,"author":{"id":"3566244878628904","authorId":"3566244878628904","name":"Wallstrtbets","avatar":"https://static.tigerbbs.com/6c38bbee1121ea92508ad9508fa15c5e","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3566244878628904","authorIdStr":"3566244878628904"},"htmlText":"Thanks, Cathy.","listText":"Thanks, Cathy.","text":"Thanks, Cathy.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883969285","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883960799,"gmtCreate":1631196685711,"gmtModify":1676530494061,"author":{"id":"3586590970630142","authorId":"3586590970630142","name":"zero79","avatar":"https://static.tigerbbs.com/18bdafe6e77141b002b8ed62dd5cc0e3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586590970630142","authorIdStr":"3586590970630142"},"htmlText":"Hope so&nbsp;","listText":"Hope so&nbsp;","text":"Hope so","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883960799","repostId":2166348079,"repostType":4,"repost":{"id":"2166348079","pubTimestamp":1631194020,"share":"https://ttm.financial/m/news/2166348079?lang=&edition=fundamental","pubTime":"2021-09-09 21:27","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2166348079","media":"Motley Fool","summary":"All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.","content":"<p>I don't know about you, but the day after Labor Day has never been a very productive <a href=\"https://laohu8.com/S/AONE.U\">one</a>. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.</p>\n<p>Wood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of <b>CRISPR Therapeutics</b> (NASDAQ:CRSP),&nbsp;<b>Invitae</b> (NYSE:NVTA), and <b><a href=\"https://laohu8.com/S/PSNL\">Personalis</a></b> (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.</p>\n<p><img src=\"https://static.tigerbbs.com/4b76837d8e082243bdf6338411e5bbc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CRISPR Therapeutics</h3>\n<p>Wood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).</p>\n<p>CRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.</p>\n<p>In fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.</p>\n<p>The stock has tumbled simply because it rose too fast in 2020.&nbsp;At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fultrasound-physician-showing-sonogram-to-patient.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"553\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Invitae</h3>\n<p>Shares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.</p>\n<p>It's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.</p>\n<p>Precision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.</p>\n<p>In 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642321%2Fbiopharma-laboratory-scene.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Personalis</h3>\n<p>Wood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.</p>\n<p>Like Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.</p>\n<p>Personalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.</p>\n<p>With insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.</p>\n<p>Personalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.</p>\n<p>Before you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSNL":"Personalis","CRSP":"CRISPR Therapeutics AG","NVTA":"Invitae Corporation"},"source_url":"https://www.fool.com/investing/2021/09/09/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166348079","content_text":"I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever.\nWood confidently bought some healthcare stocks that have been under a lot of pressure lately. Shares of CRISPR Therapeutics (NASDAQ:CRSP), Invitae (NYSE:NVTA), and Personalis (NASDAQ:PSNL) have lost more than 40% of their value since they peaked near the beginning of 2021. Here's why Wood finds them so attractive right now.\n\nImage source: Getty Images.\nCRISPR Therapeutics\nWood's been bullish on gene-editing pioneer CRISPR Therapeutics since 2017 when she began buying the stock for ARK Invest's exchange-traded funds (ETFs).\nCRISPR Therapeutics stock has tumbled around 43% since it peaked this January. Lots of shareholders have been scratching their heads because the company hasn't reported any particularly bad news this year.\nIn fact, it's been a great year for CRISPR Therapeutics and CTX001, its experimental gene therapy for transfusion-dependent thalassemia and sickle cell disease. In June, the company highlighted further evidence a single administration of CTX001 can help patients end their reliance on problematic blood transfusions.\nThe stock has tumbled simply because it rose too fast in 2020. At recent prices, CRISPR Therapeutics still boasts an enormous $9.3 billion market cap. That's still a lot for a company that won't have any products to sell for at least another year.\n\nImage source: Getty Images.\nInvitae\nShares of Invitae are down around 44% from a peak they reached in February. Despite the recent drop, shares of this medical genetics company have more than tripled since ARK Invest began buying the stock in 2016.\nIt's not hard to see why Wood's buying up shares this week at their greatly reduced price. Second-quarter sales soared 152% over the previous-year period to $116 million and they still have a lot of room to grow.\nPrecision cancer therapies can be far more effective than old-fashioned chemotherapy, but patients need tests from Invitae to know if they're eligible. A recent study suggests just 3% of colorectal cancer patients are getting their tumors screened for mutations that could make them susceptible to effective new treatment options.\nIn 2021, Invitae has already signed agreements with dozens of drugmakers who market precision cancer therapies. In a nutshell, big pharma could end up paying for lots of cancer patients to get their tumors tested by Invitae.\n\nImage source: Getty Images.\nPersonalis\nWood has been buying up shares of Personalis since its stock market debut in 2019. ARK Invest bought more shares of this young genomics company on Tuesday even though it's given up around 58% of its value since peaking this January.\nLike Invitae, Personalis is a diagnostics company working hand in hand with cancer drug developers to help them understand the complex interplay between tumors and the immune cells that surround them. Unlike its competitors, Personalis is attempting to track changes in all 20,000 human genes with a single test.\nPersonalis' ambitions are feasible thanks to a contract with the U.S. government to help complete the Million Veteran Program. This comprehensive genetic overview of over 825,000 veterans so far is already one of the largest whole-genome sequencing projects ever conducted.\nWith insight its competitors can't quite match, drugmakers are beating a path to Personalis' door. Non-government revenue in the second quarter soared 72% year over year to $8.2 million.\nPersonalis expects around $85 million in total revenue this year, which isn't nearly enough to cover operating expenses. The company expects to lose between $65 million and $70 million this year.\nBefore you follow Wood into Personalis or any of these stocks, make sure they become a small part of a well-diversified portfolio. If margins don't improve in the quarters ahead, Personalis' $977 million market cap could get a lot smaller.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":348,"commentSize":26,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}